WO2023279323A1 - Procédé de synthèse d'analogue de glp-1 - Google Patents
Procédé de synthèse d'analogue de glp-1 Download PDFInfo
- Publication number
- WO2023279323A1 WO2023279323A1 PCT/CN2021/105192 CN2021105192W WO2023279323A1 WO 2023279323 A1 WO2023279323 A1 WO 2023279323A1 CN 2021105192 W CN2021105192 W CN 2021105192W WO 2023279323 A1 WO2023279323 A1 WO 2023279323A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- fmoc
- glu
- fragment
- otbu
- resin
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 50
- 230000002194 synthesizing effect Effects 0.000 title claims abstract description 14
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 70
- 239000012634 fragment Substances 0.000 claims abstract description 69
- 239000011347 resin Substances 0.000 claims abstract description 63
- 229920005989 resin Polymers 0.000 claims abstract description 63
- 150000001413 amino acids Chemical class 0.000 claims abstract description 38
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims abstract description 23
- 239000007790 solid phase Substances 0.000 claims abstract description 9
- 125000006239 protecting group Chemical group 0.000 claims description 28
- NDKDFTQNXLHCGO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)acetic acid Chemical compound C1=CC=C2C(COC(=O)NCC(=O)O)C3=CC=CC=C3C2=C1 NDKDFTQNXLHCGO-UHFFFAOYSA-N 0.000 claims description 27
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 25
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 24
- 230000008878 coupling Effects 0.000 claims description 24
- 238000010168 coupling process Methods 0.000 claims description 24
- 238000005859 coupling reaction Methods 0.000 claims description 24
- QWXZOFZKSQXPDC-NSHDSACASA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C)C(O)=O)C3=CC=CC=C3C2=C1 QWXZOFZKSQXPDC-NSHDSACASA-N 0.000 claims description 22
- OTKXCALUHMPIGM-FQEVSTJZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 OTKXCALUHMPIGM-FQEVSTJZSA-N 0.000 claims description 20
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 claims description 20
- -1 Fmoc-Val-Ser(psiMe Chemical compound 0.000 claims description 16
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 claims description 15
- REITVGIIZHFVGU-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]propanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](COC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 REITVGIIZHFVGU-IBGZPJMESA-N 0.000 claims description 14
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 14
- HNICLNKVURBTKV-NDEPHWFRSA-N (2s)-5-[[amino-[(2,2,4,6,7-pentamethyl-3h-1-benzofuran-5-yl)sulfonylamino]methylidene]amino]-2-(9h-fluoren-9-ylmethoxycarbonylamino)pentanoic acid Chemical compound C12=CC=CC=C2C2=CC=CC=C2C1COC(=O)N[C@H](C(O)=O)CCCN=C(N)NS(=O)(=O)C1=C(C)C(C)=C2OC(C)(C)CC2=C1C HNICLNKVURBTKV-NDEPHWFRSA-N 0.000 claims description 13
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 claims description 13
- SJVFAHZPLIXNDH-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-phenylpropanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=CC=C1 SJVFAHZPLIXNDH-QFIPXVFZSA-N 0.000 claims description 12
- CBPJQFCAFFNICX-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(C)C)C(O)=O)C3=CC=CC=C3C2=C1 CBPJQFCAFFNICX-IBGZPJMESA-N 0.000 claims description 12
- LZOLWEQBVPVDPR-VLIAUNLRSA-N (2s,3r)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[(2-methylpropan-2-yl)oxy]butanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@H](OC(C)(C)C)C)C(O)=O)C3=CC=CC=C3C2=C1 LZOLWEQBVPVDPR-VLIAUNLRSA-N 0.000 claims description 12
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- 210000004899 c-terminal region Anatomy 0.000 claims description 12
- 238000003776 cleavage reaction Methods 0.000 claims description 11
- 230000007017 scission Effects 0.000 claims description 11
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 11
- JFLSOKIMYBSASW-UHFFFAOYSA-N 1-chloro-2-[chloro(diphenyl)methyl]benzene Chemical group ClC1=CC=CC=C1C(Cl)(C=1C=CC=CC=1)C1=CC=CC=C1 JFLSOKIMYBSASW-UHFFFAOYSA-N 0.000 claims description 10
- 239000006166 lysate Substances 0.000 claims description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 8
- WDGICUODAOGOMO-DHUJRADRSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-5-oxo-5-(tritylamino)pentanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)CC(=O)NC(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 WDGICUODAOGOMO-DHUJRADRSA-N 0.000 claims description 7
- OYXZPXVCRAAKCM-SANMLTNESA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-(1-tritylimidazol-4-yl)propanoic acid Chemical compound C1=NC(C[C@H](NC(=O)OC(C)(C)C)C(O)=O)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 OYXZPXVCRAAKCM-SANMLTNESA-N 0.000 claims description 7
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 claims description 7
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 7
- SWZCTMTWRHEBIN-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@@H](C(=O)O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21)C1=CC=C(O)C=C1 SWZCTMTWRHEBIN-QFIPXVFZSA-N 0.000 claims description 6
- ADOHASQZJSJZBT-SANMLTNESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-[1-[(2-methylpropan-2-yl)oxycarbonyl]indol-3-yl]propanoic acid Chemical compound C12=CC=CC=C2N(C(=O)OC(C)(C)C)C=C1C[C@@H](C(O)=O)NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ADOHASQZJSJZBT-SANMLTNESA-N 0.000 claims description 6
- UGNIYGNGCNXHTR-SFHVURJKSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylbutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](C(C)C)C(O)=O)C3=CC=CC=C3C2=C1 UGNIYGNGCNXHTR-SFHVURJKSA-N 0.000 claims description 6
- FODJWPHPWBKDON-IBGZPJMESA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-4-[(2-methylpropan-2-yl)oxy]-4-oxobutanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CC(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 FODJWPHPWBKDON-IBGZPJMESA-N 0.000 claims description 6
- QXVFEIPAZSXRGM-DJJJIMSYSA-N (2s,3s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-3-methylpentanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H]([C@@H](C)CC)C(O)=O)C3=CC=CC=C3C2=C1 QXVFEIPAZSXRGM-DJJJIMSYSA-N 0.000 claims description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 6
- 239000003875 Wang resin Substances 0.000 claims description 6
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 claims description 6
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical group C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims description 6
- WNTGYJSOUMFZEP-UHFFFAOYSA-N 2-(4-chloro-2-methylphenoxy)propanoic acid Chemical compound OC(=O)C(C)OC1=CC=C(Cl)C=C1C WNTGYJSOUMFZEP-UHFFFAOYSA-N 0.000 claims description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 239000007822 coupling agent Substances 0.000 claims description 4
- 239000012071 phase Substances 0.000 claims description 4
- 239000007821 HATU Substances 0.000 claims description 3
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- BYEAHWXPCBROCE-UHFFFAOYSA-N 1,1,1,3,3,3-hexafluoropropan-2-ol Chemical compound FC(F)(F)C(O)C(F)(F)F BYEAHWXPCBROCE-UHFFFAOYSA-N 0.000 claims description 2
- 230000005526 G1 to G0 transition Effects 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 238000005336 cracking Methods 0.000 claims description 2
- 238000010828 elution Methods 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 229910002027 silica gel Inorganic materials 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 238000004108 freeze drying Methods 0.000 claims 1
- 238000003786 synthesis reaction Methods 0.000 abstract description 21
- 230000015572 biosynthetic process Effects 0.000 abstract description 19
- 108010060325 semaglutide Proteins 0.000 abstract description 18
- YSDQQAXHVYUZIW-QCIJIYAXSA-N Liraglutide Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 YSDQQAXHVYUZIW-QCIJIYAXSA-N 0.000 abstract description 17
- 108010019598 Liraglutide Proteins 0.000 abstract description 17
- DLSWIYLPEUIQAV-UHFFFAOYSA-N Semaglutide Chemical compound CCC(C)C(NC(=O)C(Cc1ccccc1)NC(=O)C(CCC(O)=O)NC(=O)C(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CCC(NC(=O)CCCCCCCCCCCCCCCCC(O)=O)C(O)=O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(N)=O)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(CO)NC(=O)C(NC(=O)C(Cc1ccccc1)NC(=O)C(NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C(C)(C)NC(=O)C(N)Cc1cnc[nH]1)C(C)O)C(C)O)C(C)C)C(=O)NC(C)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CCCNC(N)=N)C(=O)NCC(O)=O DLSWIYLPEUIQAV-UHFFFAOYSA-N 0.000 abstract description 15
- 229960002701 liraglutide Drugs 0.000 abstract description 15
- 229950011186 semaglutide Drugs 0.000 abstract description 13
- 229920001184 polypeptide Polymers 0.000 abstract description 4
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 4
- 238000011031 large-scale manufacturing process Methods 0.000 abstract 1
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 35
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000000243 solution Substances 0.000 description 10
- 238000003756 stirring Methods 0.000 description 10
- 239000012535 impurity Substances 0.000 description 7
- 239000007791 liquid phase Substances 0.000 description 7
- 238000006467 substitution reaction Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- CMWYAOXYQATXSI-UHFFFAOYSA-N n,n-dimethylformamide;piperidine Chemical compound CN(C)C=O.C1CCNCC1 CMWYAOXYQATXSI-UHFFFAOYSA-N 0.000 description 5
- 238000010532 solid phase synthesis reaction Methods 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001308 synthesis method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- AYMLQYFMYHISQO-QMMMGPOBSA-N (2s)-3-(1h-imidazol-3-ium-5-yl)-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CN=CN1 AYMLQYFMYHISQO-QMMMGPOBSA-N 0.000 description 2
- HOZZVEPRYYCBTO-UHFFFAOYSA-N 2-(9h-fluoren-9-ylmethoxycarbonylamino)-2-methylpropanoic acid Chemical compound C1=CC=C2C(COC(=O)NC(C)(C)C(O)=O)C3=CC=CC=C3C2=C1 HOZZVEPRYYCBTO-UHFFFAOYSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- DBTMQODRSDEGRZ-UHFFFAOYSA-N 9h-fluoren-9-ylmethyl n-(2-oxoethyl)carbamate Chemical compound C1=CC=C2C(COC(=O)NCC=O)C3=CC=CC=C3C2=C1 DBTMQODRSDEGRZ-UHFFFAOYSA-N 0.000 description 2
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 102100040918 Pro-glucagon Human genes 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 238000009833 condensation Methods 0.000 description 2
- 230000005494 condensation Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- BNJOQKFENDDGSC-UHFFFAOYSA-N octadecanedioic acid Chemical compound OC(=O)CCCCCCCCCCCCCCCCC(O)=O BNJOQKFENDDGSC-UHFFFAOYSA-N 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OJBNDXHENJDCBA-QFIPXVFZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-(prop-2-enoxycarbonylamino)hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)OCC=C)C(=O)O)C3=CC=CC=C3C2=C1 OJBNDXHENJDCBA-QFIPXVFZSA-N 0.000 description 1
- LQQXBYSAGYOQJW-ZAQUEYBZSA-N (2s)-2-(9h-fluoren-9-ylmethoxycarbonylamino)-6-[[(4s)-4-(hexadecanoylamino)-5-[(2-methylpropan-2-yl)oxy]-5-oxopentanoyl]amino]hexanoic acid Chemical compound C1=CC=C2C(COC(=O)N[C@@H](CCCCNC(=O)CC[C@H](NC(=O)CCCCCCCCCCCCCCC)C(=O)OC(C)(C)C)C(O)=O)C3=CC=CC=C3C2=C1 LQQXBYSAGYOQJW-ZAQUEYBZSA-N 0.000 description 1
- DHBXNPKRAUYBTH-UHFFFAOYSA-N 1,1-ethanedithiol Chemical compound CC(S)S DHBXNPKRAUYBTH-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- RUVRGYVESPRHSZ-UHFFFAOYSA-N 2-[2-(2-azaniumylethoxy)ethoxy]acetate Chemical compound NCCOCCOCC(O)=O RUVRGYVESPRHSZ-UHFFFAOYSA-N 0.000 description 1
- HXMVNCMPQGPRLN-UHFFFAOYSA-N 2-hydroxyputrescine Chemical compound NCCC(O)CN HXMVNCMPQGPRLN-UHFFFAOYSA-N 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000051325 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000007446 Glucagon-Like Peptide-1 Receptor Human genes 0.000 description 1
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- WOOWBQQQJXZGIE-UHFFFAOYSA-N n-ethyl-n-propan-2-ylpropan-2-amine Chemical compound CCN(C(C)C)C(C)C.CCN(C(C)C)C(C)C WOOWBQQQJXZGIE-UHFFFAOYSA-N 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- USFPINLPPFWTJW-UHFFFAOYSA-N tetraphenylphosphonium Chemical compound C1=CC=CC=C1[P+](C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 USFPINLPPFWTJW-UHFFFAOYSA-N 0.000 description 1
- HNKJADCVZUBCPG-UHFFFAOYSA-N thioanisole Chemical compound CSC1=CC=CC=C1 HNKJADCVZUBCPG-UHFFFAOYSA-N 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
- C07K1/08—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using activating agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the invention relates to the technical field of polypeptide synthesis, in particular to a method for synthesizing GLP-1 analogues.
- GLP-1 glucagon-like peptide-1
- GLP-1 receptor binds to the GLP-1 receptor and acts on pancreatic ⁇ cells to increase the biosynthesis and secretion of insulin; at the same time Increase the number of islet ⁇ cells, inhibit the secretion of glucagon; inhibit appetite and food intake, delay the emptying of gastric contents, etc.
- GLP-1 analogues are clinically developed for the treatment of type II diabetes and obesity, including liraglutide (Liraglutide), semaglutide (Semaglutide), etc.
- the peptide sequence of liraglutide is:
- the peptide sequence of semaglutide is:
- the existing methods for preparing GLP-1 analogues can be roughly divided into two categories: genetic recombination methods and chemical synthesis methods.
- Genetic recombination method Firstly, construct a recombinant expression vector, ferment, and purify the main chain fragment of the peptide, and then chemically connect the side chain fragment to the main chain fragment to obtain the crude peptide of the target product, such as patents CN1271086, CN105154498, etc.
- the development cycle of this method is long, the technology is difficult, and the impurities are not easy to control.
- Chemical synthesis methods including the following:
- Fmoc/tBu strategy is used for solid-phase synthesis, temporary protecting groups such as Mtt, Aloc or ivDde are selected for lysine side chains, and the main chains are coupled one by one from the C-terminus to the N-terminus according to the peptide sequence, and then removed
- the side chain amino acids are coupled in sequence according to the peptide sequence, and finally the target product crude peptide is obtained by trifluoroacetic acid cleavage, such as patents CN102286092, CN106928343, CN109369798, etc.
- Patent CN106749613 first synthesizes the following three fragments by solid phase or liquid phase method: [1-16], [17-22] and [23-31], then condenses the fragments in the liquid phase to obtain a fully protected peptide, and finally trifluoroacetic acid Cleavage to obtain crude semaglutide peptide.
- Patent CN109456401 first synthesizes six fragments by liquid phase or solid phase method: [1-4], [5-9], [10-16], [17-22], [23-27], [28-31], Then the fragments were coupled to a resin to obtain a peptide resin, and finally trifluoroacetic acid was cleaved to obtain a crude semaglutide peptide.
- Patent CN11037278 firstly synthesized Oct- ⁇ -Glu(tBu)-AEEA-AEEA-OH side chain fragment and Fmoc-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(tBu)- Val-OH hexapeptide fragments, and then these two fragments and other amino acids are coupled to the resin to obtain a peptide resin, and finally trifluoroacetic acid is cleaved to obtain a crude semaglutide peptide.
- Fragment [17-22] selected by patent CN106749613 in fragment condensation, fragment [5-9], [17-22] and [23-27] selected by patent CN109456401, fragment Fmoc-Thr(tBu)-Phe selected by patent CN11037278 -Thr(tBu)-Ser(tBu)-Asp(tBu)-Val-OH will racemize the C-terminal amino acid during coupling, resulting in more racemic impurities, and the purity of the crude peptide is low. At the same time, it is cumbersome to use liquid phase to synthesize fragments. Therefore, it is necessary to provide a synthetic method of GLP-1 analogs with high purity and yield of crude peptide and less Des-Thr 5 impurities to adapt to industrial production.
- the purpose of the present invention is to provide a method for synthesizing GLP-1 analogues, the purity and yield of the crude peptide obtained by the method are high, the Des-Thr 5 impurity is less, and the operation is simple, which is suitable for industrial production.
- the invention provides a method for synthesizing GLP-1 analogues, comprising the following steps:
- Step 1 Synthesizing a fragment 1 coupled with a protecting group at the N-terminal of the amino acid sequence shown in SEQ ID NO: 1, on the His side chain, and on the Glu side chain;
- Step 2 Synthesizing Fragment 2 with protective groups coupled to the N-terminal of the amino acid sequence shown in SEQ ID NO: 2, on the Thr side chain, on the Ser side chain, on the Asp side chain, on the Tyr side chain, and on the Glu side chain;
- Step 3 sequentially coupling the amino acid shown in SEQ ID NO:3, Fragment 2 and Fragment 1 on the solid phase carrier in the order from the C-terminal to the N-terminal to obtain a peptide resin;
- Step 4 Cleavage the peptide resin to obtain crude peptide.
- the present invention firstly synthesizes the fragment 1 to 4 of the N-terminal of the GLP-1 analogue, the fragment 2 of the 5th to 12th position, and then sequentially couples SEQ ID NO:
- the amino acid shown in 2 Fragment 2 and Fragment 1 are obtained from peptide resin, and cleaved to obtain crude peptide.
- the crude peptide obtained by the synthesis method of the invention has high purity, high yield and less Des-Thr5 impurities.
- the purity of the crude peptide is 80% to 82%, the yield is 38% to 40%, and the impurity of Des-Thr 5 is about 0.07 to 0.08%. .
- the step 1 is specifically: sequentially coupling Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-X-OH and Boc-His(Trt)-OH, piperidine removes the Fmoc protecting group, and fragment 1 is obtained by weak acid cleavage.
- the peptide sequence of Fragment 1 is Boc-His(Trt)-X-Glu(OtBu)-Gly-OH.
- X is Ala or Aib.
- the step 2 is specifically: according to the sequence from the C-terminus to the N-terminus of the amino acid sequence shown in SEQ ID NO: 2, sequentially coupling Fmoc-Gly-OH, Fmoc-Glu(OtBu)- OH, Fmoc-Leu-OH, Fmoc-Tyr(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-Ser(psiMe, Mepro), Fmoc-Asp(OtBu)-OH, Fmoc-Ser( tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Phe-OH and Fmoc-Thr(tBu)-OH, piperidine removes the Fmoc protecting group, and weak acid cleavage to obtain Fragment 2.
- the weak acid used in the weak acid cracking is one or more of trifluoroethanol, hexafluoroisopropanol, acetic acid and trifluoroacetic acid.
- step 3 of the present invention the coupling of the amino acids shown in SEQ ID NO:3 is specifically to couple the protected amino acids one by one in the order from the C-terminal to the N-terminal of the amino acid sequence shown in SEQ ID NO:3; the protected amino acid is the protected group protected amino acids.
- the protected amino acid is Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Y)-OH, Fmoc-Ala-OH , Fmoc-Ala-OH and Fmoc-Gln(Trt)-OH.
- Y is Pal-Glu-OtBu or Oct(OtBu)-Glu-OtBu-AEEA-AEEA.
- the peptide sequence of the GLP-1 analog is (N-terminal to C-terminal): H-His-X-Glu-Gly-Thr 5 -Phe-Thr-Ser-Asp-Val 10 -Ser-Ser-Tyr -Leu-Glu 15 -Gly-Gln-Ala-Ala-Lys 20 (Y)-Glu-Phe-Ile-Ala-Trp 25 -Leu-Val-Arg-Gly-Arg 30 -Gly-OH.
- X is Ala
- Y is Pal-Glu-OtBu
- the synthetic GLP-1 analogue is liraglutide, and its peptide sequence is:
- X is Aib
- Y is Oct(OtBu)-Glu-OtBu-AEEA-AEEA
- the synthetic GLP-1 analog is semaglutide, and its peptide sequence is:
- the type of solid resin is not particularly limited, and the types commonly used in the field are sufficient.
- the solid resin used in steps 1-3 is 2-chlorotrityl chloride resin or Wang resin.
- the removal agent used to remove the N-terminal Fmoc protecting group in the present invention is preferably piperidine solution. Including but not limited to this.
- the coupling agent for coupling is DIPCDI/HOBt, PyBop/HOBt/DIPEA, HBTU/HOBt/DIPEA, DIPCDI/HOAt, HATU/HOAt/DIPEA and PyAop/HOAt/DIPEA one or several.
- the lysate of the lysis is a trifluoroacetic acid solution containing a capture agent, and the capture agent is one or more of PhSMe, PhOH, H 2 O, TIS, PhOMe, and EDT.
- the lysate is a combination of TFA, H 2 O and PhOH, wherein the volume ratio of TFA, H 2 O and PhOH is 90:5:5.
- the present invention firstly synthesizes the fragment 1 of the 1st to 4th position of the N-terminal of the GLP-1 analogue, and the fragment 2 of the 5th to 12th position of the N-terminal, and then sequentially couples the SEQ ID NO on the solid phase carrier according to the order from the C-terminal to the N-terminal : amino acid shown in 3, fragment 2 and fragment 1, obtain peptide resin, crack, obtain crude peptide.
- the crude peptide obtained by the synthesis method of the invention has high purity and high total yield.
- Fig. 1 shows the preparation process flowchart of GLP-1 analogue
- Figure 2 shows a typical chromatogram of liraglutide fragment one
- Figure 3 shows a typical chromatogram of liraglutide crude peptide
- Figure 4 shows a typical chromatogram of semaglutide fragment one
- Fig. 5 shows the typical chromatogram of semaglutide crude peptide
- Figure 6 shows a typical chromatogram of a refined peptide.
- the present invention provides a method for synthesizing GLP-1 analogues, and those skilled in the art can refer to the content of this article and appropriately improve the process parameters to realize it.
- all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention.
- the method and application of the present invention have been described through preferred embodiments, and relevant personnel can obviously make changes or appropriate changes and combinations to the method and application herein without departing from the content, spirit and scope of the present invention to realize and apply the present invention Invent technology.
- the reagents and instruments used in the present invention are all common commercial products and can be purchased in the market.
- the invention provides a method for synthesizing GLP-1 analogues, comprising the following steps:
- Step 1 Synthesizing a fragment 1 coupled with a protecting group at the N-terminal of the amino acid sequence shown in SEQ ID NO: 1, on the His side chain, and on the Glu side chain;
- Step 2 Synthesizing Fragment 2 with protective groups coupled to the N-terminal of the amino acid sequence shown in SEQ ID NO: 2, on the Thr side chain, on the Ser side chain, on the Asp side chain, on the Tyr side chain, and on the Glu side chain;
- Step 3 sequentially coupling the amino acid shown in SEQ ID NO:3, Fragment 2 and Fragment 1 on the solid phase carrier in the order from the C-terminal to the N-terminal to obtain a peptide resin;
- Step 4 Cleavage the peptide resin to obtain crude peptide.
- the peptide sequence of the GLP-1 analog is (N-terminal to C-terminal): H-His-X-Glu-Gly-Thr 5 -Phe-Thr-Ser-Asp-Val 10 -Ser-Ser-Tyr -Leu-Glu 15 -Gly-Gln-Ala-Ala-Lys 20 (Y)-Glu-Phe-Ile-Ala-Trp 25 -Leu-Val-Arg-Gly-Arg 30 -Gly-OH (Formula I).
- the synthesis strategy provided by the present invention is: the main chain peptide sequence of the above-mentioned GLP-1 analog is divided into three parts, fragment one (SEQ ID NO:1), fragment two (SEQ ID NO:2) and the remaining amino acids (SEQ ID NO: 3).
- SEQ ID NO:1 fragment one
- SEQ ID NO:2 fragment two
- SEQ ID NO: 3 the remaining amino acids
- the amino acid sequence shown in SEQ ID NO: 1 N terminal ⁇ C terminal
- the specific sequence is: His-X-Glu-Gly, wherein, X is Ala or Aib.
- amino acid sequence shown in SEQ ID NO: 2 is (N-terminal ⁇ C-terminal), which is the sequence numbered 5-16 in the peptide sequence shown in formula I, and the specific sequence is: Thr-Phe-Thr-Ser-Asp- Val-Ser-Ser-Tyr-Leu-Glu-Gly.
- amino acid sequence (N-terminal ⁇ C-terminal) shown in SEQ ID NO:3 is the sequence numbered 17th to 31st in the peptide sequence shown in formula I, and the specific sequence is: Gln-Ala-Ala-Lys(Y)- Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly.
- Y is Pal-Glu-OtBu or Oct(OtBu)-Glu-OtBu-AEEA-AEEA.
- Fragment 1 The peptide sequence of Fragment 1 is Boc-His(Trt)-X-Glu(OtBu)-Gly-OH, wherein X is Ala or Aib. Using 2-chlorotrityl chloride resin as a carrier, according to the polypeptide solid-phase synthesis method, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-X-OH and Boc-His(Trt)-OH.
- Fragment 2 The peptide sequence of Fragment 2 is Fmoc-Thr(tBu)-Phe-Thr(tBu)-Ser(tBu)-Asp(OtBu)-Val-Ser(psiMe,Mepro)-Ser(tBu) -Tyr(tBu)-Leu-Glu(OtBu)-Gly-OH.
- 2-chlorotrityl chloride resin as a carrier, according to the polypeptide solid-phase synthesis method, Fmoc-Gly-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Leu-OH, Fmoc-Leu-OH, Fmoc-Tyr(Boc)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Val-Ser(psiMe, Mepro), Fmoc-Asp(OtBu)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr (tBu)-OH, Fmoc-Phe-OH and Fmoc-Thr(tBu)-OH.
- Synthesis of peptide resin use 2-chlorotrityl chloride resin or Wang resin as the carrier, according to the peptide solid-phase synthesis method, according to the peptide sequence, sequentially couple Fmoc-Gly-OH, Fmoc from C-terminal to N-terminal -Arg(Pbf)-OH, Fmoc-Gly-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Val-OH, Fmoc-Leu-OH, Fmoc-Trp(Boc)-OH, Fmoc-Ala-OH, Fmoc-Ile-OH, Fmoc-Phe-OH, Fmoc-Glu(OtBu)-OH, Fmoc-Lys(Y)-OH, Fmoc-Ala-OH, Fmoc-Ala-OH, Fmoc-Gln(Trt)-OH , fragment two and fragment one, wherein Y is Pal-Glu
- Embodiment 2 the synthesis of fragment two
- Embodiment 6 the synthesis of semaglutide peptide resin
- Embodiment 7 the synthesis of semaglutide
- the crude peptide obtained in Example 4 or 7 was prepared and purified by high performance liquid chromatography, with tetraalkylsilane bonded silica gel as the stationary phase, 0.2% acetic acid solution as the mobile phase A, and acetonitrile as the mobile phase B , monitoring wavelength 280nm, gradient elution to collect target peak fractions, concentrated, freeze-dried to obtain liraglutide or semaglutide fine peptide, purity 99.7%, (chromatogram shown in Figure 6).
- the purity of the obtained crude peptide was 58%, and the total yield was about 15%.
Abstract
La présente invention relève du domaine technique de la synthèse de polypeptides, en particulier un procédé de synthèse d'un analogue de GLP-1. Dans la présente invention, le fragment 1 et le fragment 2 respectivement aux positions 1-4 et les positions 5-12 d'une extrémité N-terminale d'un analogue de GLP-1 sont d'abord synthétisés, puis les acides aminés restants, le fragment 2 et le fragment 1 sont séquentiellement couplés sur un support en phase solide dans une séquence allant d'une extrémité C-terminale à une extrémité N-terminale pour obtenir une résine peptidique qui est clivée pour obtenir un peptide brut. Les analogues de GLP-1, à savoir le liraglutide et le semaglutide, sont synthétisés à l'aide d'une stratégie de synthèse spécifique selon la présente invention, de sorte que la pureté et le rendement total du peptide brut sont élevés, le procédé de synthèse est simple, et le procédé est approprié pour une production à grande échelle.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/105192 WO2023279323A1 (fr) | 2021-07-08 | 2021-07-08 | Procédé de synthèse d'analogue de glp-1 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/105192 WO2023279323A1 (fr) | 2021-07-08 | 2021-07-08 | Procédé de synthèse d'analogue de glp-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023279323A1 true WO2023279323A1 (fr) | 2023-01-12 |
Family
ID=84800286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/105192 WO2023279323A1 (fr) | 2021-07-08 | 2021-07-08 | Procédé de synthèse d'analogue de glp-1 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023279323A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117024528A (zh) * | 2023-07-07 | 2023-11-10 | 杭州信海医药科技有限公司 | 一种Retatrutide的制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016046753A1 (fr) * | 2014-09-23 | 2016-03-31 | Novetide, Ltd. | Synthèse de peptides glp-1 |
CA3046425A1 (fr) * | 2016-12-10 | 2018-06-14 | Biocon Limited | Synthese de liraglutide |
WO2020074583A1 (fr) * | 2018-10-09 | 2020-04-16 | Fresenius Kabi Ipsum S.R.L. | Procédé de fabrication d'analogues de glp-1 |
WO2020188510A2 (fr) * | 2019-03-19 | 2020-09-24 | Enzene Biosciences Limited | Procédé de préparation d'agonistes du récepteur du peptide-1 de type glucagon (glp-1) et de leurs analogues |
WO2021007701A1 (fr) * | 2019-07-12 | 2021-01-21 | Shanghai Space Peptides Pharmaceutical Co., Ltd. | Procédé de préparation de liraglutide par synthèse de peptides en phase solide |
WO2021070202A1 (fr) * | 2019-10-09 | 2021-04-15 | Prasad Alaparthi Lakshmi | Procédé de préparation d'un analogue du glp-1 par synthèse de peptides en phase solide |
-
2021
- 2021-07-08 WO PCT/CN2021/105192 patent/WO2023279323A1/fr unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016046753A1 (fr) * | 2014-09-23 | 2016-03-31 | Novetide, Ltd. | Synthèse de peptides glp-1 |
CA3046425A1 (fr) * | 2016-12-10 | 2018-06-14 | Biocon Limited | Synthese de liraglutide |
WO2020074583A1 (fr) * | 2018-10-09 | 2020-04-16 | Fresenius Kabi Ipsum S.R.L. | Procédé de fabrication d'analogues de glp-1 |
WO2020188510A2 (fr) * | 2019-03-19 | 2020-09-24 | Enzene Biosciences Limited | Procédé de préparation d'agonistes du récepteur du peptide-1 de type glucagon (glp-1) et de leurs analogues |
WO2021007701A1 (fr) * | 2019-07-12 | 2021-01-21 | Shanghai Space Peptides Pharmaceutical Co., Ltd. | Procédé de préparation de liraglutide par synthèse de peptides en phase solide |
WO2021070202A1 (fr) * | 2019-10-09 | 2021-04-15 | Prasad Alaparthi Lakshmi | Procédé de préparation d'un analogue du glp-1 par synthèse de peptides en phase solide |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN117024528A (zh) * | 2023-07-07 | 2023-11-10 | 杭州信海医药科技有限公司 | 一种Retatrutide的制备方法 |
CN117024528B (zh) * | 2023-07-07 | 2024-03-22 | 杭州信海医药科技有限公司 | 一种Retatrutide的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018032843A1 (fr) | Procédé de synthèse de sémaglutide | |
US9260474B2 (en) | Method for solid phase synthesis of liraglutide | |
CN106699871B (zh) | 一种利拉鲁肽的制备方法 | |
JP6991196B2 (ja) | グルカゴン様ペプチドを製造するための方法 | |
CN110372785B (zh) | 一种索马鲁肽的合成方法 | |
US20130030148A1 (en) | Process for the synthesis of (aib8,35)hglp-1(7-36)-nh2 | |
WO2023089594A1 (fr) | Procédé de préparation de tirzépatide ou de sel pharmaceutiquement acceptable de celui-ci | |
KR20210141600A (ko) | 글루카곤 유사 펩티드-1(glp-1) 수용체 작용제 및 이의 유사물의 제조 방법 | |
WO2023279323A1 (fr) | Procédé de synthèse d'analogue de glp-1 | |
KR19990082403A (ko) | 혈관작용성 장 펩타이드 유사체의 합성 방법 | |
CN107778351B (zh) | 一种全固相合成奥曲肽的方法 | |
WO2019019492A1 (fr) | Méthode de synthèse de pt141 | |
CN106432468A (zh) | 一种制备艾塞那肽的固相合成方法 | |
WO2020000555A1 (fr) | Procédé de préparation de tériparatide | |
WO2023279324A1 (fr) | Procédé de synthèse d'un analogue de glp-1 | |
Mihara et al. | Synthesis of the 60 amino acid homeo domain and smaller fragments of the Drosophila gene regulatory protein Antennapedia by a segment synthesis-condensation approach | |
WO2017114192A1 (fr) | Méthode de préparation du lixisénatide | |
CN105713082B (zh) | 一种制备利西拉来的方法 | |
CN110845600A (zh) | 一种制备利拉鲁肽的方法 | |
CN113135988B (zh) | 一种胸腺肽β4的制备方法 | |
CN113512105B (zh) | 一种依降钙素的制备方法 | |
CN111018963B (zh) | 一种胰高血糖素的制备方法 | |
CN110964097B (zh) | 一种固相片段法合成艾塞那肽 | |
CN115594754A (zh) | 一种特立帕肽的制备方法 | |
WO2023234860A1 (fr) | Procédé de préparation du glucagon-like peptide-1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21948819 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |